Results 151 to 160 of about 178,517 (322)
Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry [PDF]
, 2000 Hirokazu Kanegane +9 more
openalex +1 more source
Bruton's tyrosine kinase is a substrate of calpain in human platelets
FEBS Letters, 2001 Platelet‐associated Bruton's tyrosine kinase (Btk) was completely cleaved if treated with calcium ionophore A23187 with appearance of a proteolytic product of 27 kDa size. Aggregation with thrombin also induced about 10% degradation of Btk after 30 min. Calpain inhibitors prevented Btk degradation in both.
Saikat Mukhopadhyay +3 more
openaire +3 more sources
Informatics in Medicine Unlocked, 2019 Rheumatoid Arthritis (RA) is a multifactorial auto-immune disease of unknown etiology. Activation of innate immune systems including B and T lymphocytes is the earliest step in RA pathogenesis.
Arulmozhi S +4 more
doaj
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.
American Journal of Physiology - Lung cellular and Molecular Physiology, 2018 Infection with seasonal influenza A virus (IAV) leads to lung inflammation and respiratory failure, a main cause of death in influenza-infected patients.
J. Florence +5 more
semanticscholar +1 more source
Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley +1 more source
Characterizing immunomodulatory properties of a novel therapeutic approach for multiple sclerosis - Inhibition of Bruton's tyrosine kinase [PDF]
Multiple Sclerosis is a complex and challenging chronic disease of the central nervous system (CNS), characterized by inflammation, demyelination, and neurodegeneration.
Dybowski, Sarah
core +1 more source
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era
Internal Medicine Journal, EarlyView.Abstract Background Allogeneic haemopoietic stem cell transplantation (HSCT) is an effective therapy with curative potential for patients with high‐risk or relapsed/refractory chronic lymphocytic leukaemia (CLL). There are limited data on the use and outcomes of HSCT in the modern era of CLL treatment.
Luani Barge +22 more
wiley +1 more source
eJHaemThe use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj +1 more source
eJHaem, Volume 6, Issue 4, August 2025.ABSTRACT Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects. Methods We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation.
Benjamin Heyman +2 more
wiley +1 more source
Cancer treatment and survivorship statistics, 2025
CA: A Cancer Journal for Clinicians, Volume 75, Issue 4, Page 308-340, July/August 2025.Abstract The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National ...
Nikita Sandeep Wagle +9 more
wiley +1 more source